SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Viemed Healthcare, Inc. (VMD) trades at a trailing P/E of 24.0, forward P/E of 20.0. Trailing earnings yield is 4.17%, forward earnings yield 5.00%. PEG 0.75 (Peter Lynch undervalued ≤1.0). Graham Number is $5.78.
Criteria proven by this page:
- VALUE (70/100, Pass) — P/E is below market average (24.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.75); earnings yield beats bond yields (4.17%).
- Forward P/E 20.0 (down from trailing 24.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.75 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.17% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.00% as earnings recover.
Overall SharesGrow Score: 78/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
70/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VMD
Valuation Multiples
P/E (TTM)24.0
Forward P/E20.0
PEG Ratio0.75
Forward PEG0.67
P/B Ratio2.53
P/S Ratio1.35
EV/EBITDA7.0
Per Share Data
EPS (TTM)$0.39
Forward EPS (Est.)$0.48
Book Value / Share$3.78
Revenue / Share$7.11
FCF / Share$0.31
Yields & Fair Value
Earnings Yield4.17%
Forward Earnings Yield5.00%
Dividend Yield0.00%
Graham Number$5.78
SharesGrow IV$29.67 (+208.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
55.4 |
-0.57 |
5.28 |
2.17 |
- |
| 2017 |
8.3 |
0.01 |
2.86 |
1.45 |
- |
| 2018 |
14.1 |
0.62 |
4.11 |
2.21 |
- |
| 2019 |
27.4 |
-1.85 |
5.35 |
2.91 |
- |
| 2020 |
9.5 |
0.03 |
3.68 |
2.29 |
- |
| 2021 |
22.6 |
-0.31 |
2.17 |
1.76 |
- |
| 2022 |
47.0 |
-1.35 |
3.01 |
2.10 |
- |
| 2023 |
29.4 |
0.37 |
2.64 |
1.65 |
- |
| 2024 |
27.6 |
3.72 |
2.37 |
1.39 |
- |
| 2025 |
19.4 |
0.62 |
2.04 |
1.07 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.03 |
$31.36M |
$1.23M |
3.9% |
| 2017 |
$0.22 |
$46.93M |
$8.18M |
17.4% |
| 2018 |
$0.26 |
$65.27M |
$10.18M |
15.6% |
| 2019 |
$0.22 |
$80.26M |
$8.53M |
10.6% |
| 2020 |
$0.82 |
$131.31M |
$31.53M |
24% |
| 2021 |
$0.22 |
$117.06M |
$9.13M |
7.8% |
| 2022 |
$0.15 |
$138.83M |
$6.22M |
4.5% |
| 2023 |
$0.25 |
$183.01M |
$10.24M |
5.6% |
| 2024 |
$0.28 |
$224.26M |
$11.27M |
5% |
| 2025 |
$0.37 |
$270.28M |
$14.93M |
5.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.48 |
$0.48 – $0.48 |
$315.45M |
$315.18M – $315.72M |
1 |
| 2027 |
$0.62 |
$0.62 – $0.62 |
$362.7M |
$362.39M – $363.01M |
1 |
| 2028 |
$0.85 |
$0.85 – $0.85 |
$416M |
$415.85M – $416.15M |
1 |
